on Piramal Pharma Solutions
Piramal Pharma Solutions Launches Advanced Facility in Michigan
Piramal Pharma Solutions (PPS) has unveiled a new, state-of-the-art payload-linker development suite at its Riverview, Michigan facility. This addition aims to bolster the company's capacity to support global payload-linker development and manufacturing, crucial for complex therapies like antibody-drug conjugates (ADCs).
This expansion is part of a broader $90 million investment to enhance PPS's U.S.-based manufacturing capabilities. Alongside this development, enhancements are planned for their sterile injectables facility in Lexington, Kentucky. Such strategic moves reflect PPS's commitment to swift and reliable delivery of innovative therapies.
Peter DeYoung, CEO of Piramal Global Pharma, highlighted the milestone, emphasizing the strengthened supply chain security and development acceleration for critical medicines. With over 60 years in drug substance development, the Riverview site is poised to meet the rising demand for ADCs.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Piramal Pharma Solutions news